Cargando…

Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial

OBJECTIVE: To assess the efficacy and safety of ultra-low dose 0.005% estriol vaginal gel in women with breast cancer receiving nonsteroidal aromatase inhibitors (NSAIs) and experiencing treatment-related vulvovaginal symptoms and signs. METHODS: Women with hormone receptor-positive early breast can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirschberg, Angelica Lindén, Sánchez-Rovira, Pedro, Presa-Lorite, Jesús, Campos-Delgado, Miriam, Gil-Gil, Miguel, Lidbrink, Elisabet, Suárez-Almarza, Javier, Nieto-Magro, Concepción
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott-Raven Publishers 2020
Materias:	Original Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188038/ https://www.ncbi.nlm.nih.gov/pubmed/32049923 http://dx.doi.org/10.1097/GME.0000000000001497

Ejemplares similares

Early Effect of 0.005% Estriol Vaginal Gel on Symptoms and Signs of Vulvovaginal Atrophy
por: Lázaro-Carrasco de la Fuente, Jesús, et al.
Publicado: (2022)

A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting
por: Sánchez‐Rovira, Pedro, et al.
Publicado: (2020)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

Retract p < 0.005 and propose using JASP, instead
por: Perezgonzalez, Jose D., et al.
Publicado: (2018)

The assessment of intrinsic credibility and a new argument for p < 0.005
por: Held, Leonhard
Publicado: (2019)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
por: Molinelli, Elisa, et al.
Publicado: (2020)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
por: Radcliffe, Nathan, et al.
Publicado: (2020)

Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study
por: Garcia de Arriba, Susana, et al.
Publicado: (2022)

The temperature stability of 0.005°C for the concrete floor in the CERN Transfer Tunnel #1 hosting the Precision Laser Inclinometer
por: Azaryan, N, et al.
Publicado: (2017)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

Garnet-Based All-Ceramic Lithium Battery Enabled by Li(2.985)B(0.005)OCl Solder
por: Feng, Wuliang, et al.
Publicado: (2020)

Noninferiority Study Comparing Latanoprost 0.005% Without Versus With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
por: Wirta, David, et al.
Publicado: (2022)

Trifarotene 0.005% Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: a Case Series
por: Del Rosso, James Q., et al.
Publicado: (2022)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Sodium Hypochlorite 0.005% Versus Placebo in the Treatment of Mild to Moderate Acne: A Double-Blind Randomized Controlled Trial
por: Dorostkar, Azadeh, et al.
Publicado: (2021)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Özkurt, Yelda Buyru, et al.
Publicado: (2009)

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
por: Weinreb, Robert N, et al.
Publicado: (2015)

Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
por: Shen Lee, Bridgitte, et al.
Publicado: (2022)

Plague mitigation for prairie dog and black-footed ferret conservation: Degree and duration of flea control with 0.005% fipronil grain bait
por: Eads, David A., et al.
Publicado: (2023)

Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors
por: Donders, G., et al.
Publicado: (2015)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
por: Inoue, Kenji, et al.
Publicado: (2014)

Impact of nonsteroidal aromatase inhibitors on steroid profile in a Chinese population
por: Xing, Yanyi, et al.
Publicado: (2017)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: Godfrey, David A, et al.
Publicado: (2009)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits
por: Rubenicia, Ana Marie L., et al.
Publicado: (2021)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
por: Hagras, Sherein M, et al.
Publicado: (2021)

An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (w/v) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
por: Freiberg, Josefine C., et al.
Publicado: (2022)

Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy
por: Jaisamrarn, U., et al.
Publicado: (2013)

The metabolic effects of estriol in female rat liver.
por: Yang, J. M., et al.
Publicado: (1999)

Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study
por: Donders, Gilbert, et al.
Publicado: (2014)

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan(®) and Arulatan(®)) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
por: Brant Fernandes, Rodrigo A, et al.
Publicado: (2019)

Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study
por: Wang, Xue, et al.
Publicado: (2020)

CORRIGENDUM to “Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study”
Publicado: (2020)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
por: Inoue, Kenji, et al.
Publicado: (2012)

Estriol and Progesterone: A New Role for Sex Hormones
por: Draca, Sanja
Publicado: (2006)

An estriol-eluting pessary to treat pelvic organ prolapse
por: Long, Jingjunjiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d8snuv71s6uu6p8li4imh3bl5v